Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 37.40 | 43.83 | 79.10 | 66.27 | 63.24 |
Total Expenses | 29.17 | 33.41 | 77.27 | 64.42 | 62.57 |
Profit Before Tax | 8.22 | 11.37 | 5.24 | 1.85 | 0.67 |
Profit After Tax | 7.59 | 11.37 | 4.62 | 1.85 | 0.71 |
Operating Profit after Depreciation | 25.28 | 21.32 | 4.77 | 7.34 | 7.50 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 187.19 | 179.19 | 204.11 | 247.98 | 242.75 |
Total Non Current Assets | 312.68 | 323.09 | 205.53 | 250.03 | 244.74 |
Total Current Assets | 53.22 | 53.91 | 80.61 | 67.30 | 86.53 |
TOTAL ASSETS | 365.90 | 377 | 286.15 | 317.33 | 331.26 |
Total Shareholder's Fund | 180.59 | 193.33 | 184.50 | 141.65 | 140.37 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 41.72 | 15.23 | 16.47 | 19.86 | 17.43 |
Net Cash used in Investing Activities | -8.28 | -133.36 | -10.05 | -3.29 | -6.30 |
Net Cash used in Financing Activities | -18.68 | 85.17 | 22.05 | -15.63 | -7.88 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 37.35 | 43.83 | 40.81 | 23.33 | 26.85 |
Total Expenses | 29.15 | 33.40 | 38.02 | 21.95 | 26.33 |
Profit Before Tax | 8.20 | 11.48 | 6.20 | 1.38 | 0.52 |
Profit After Tax | 7.56 | 11.48 | 5.58 | 1.39 | 0.56 |
Operating Profit after Depreciation | 25.26 | 21.32 | 4.84 | 4.12 | 4.19 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 187.19 | 179.19 | 184.98 | 137.52 | 134.69 |
Total Non Current Assets | 336.21 | 326.29 | 192.92 | 237.04 | 234.14 |
Total Current Assets | 52.63 | 53.36 | 63.43 | 41.15 | 56.55 |
TOTAL ASSETS | 388.84 | 379.64 | 256.35 | 278.19 | 290.68 |
Total Shareholder's Fund | 203.55 | 195.99 | 184.51 | 149.55 | 148.23 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 22.51 | 12.87 | 22.97 | 10.87 | 7.12 |
Net Cash used in Investing Activities | 9.67 | -146.53 | -42.28 | -0.71 | -0.56 |
Net Cash used in Financing Activities | -17.45 | 103.19 | 51.32 | -10.09 | -7.18 |
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | - | - | - | - | - |
Total Expenses | 2.13 | 1.83 | 1.44 | 2.41 | 2.49 |
Profit Before Tax | 0.89 | 0.52 | 0.46 | 0.46 | 3.50 |
Profit After Tax | 0.90 | 0.52 | 0.46 | 0.46 | 3.41 |
Operating Profit after Depreciation | 6.43 | 5.78 | 6.17 | 5.33 | 8.31 |
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | - | - | - | - | - |
Total Expenses | 2.12 | 1.81 | 1.43 | 2.40 | 2.48 |
Profit Before Tax | 0.90 | 0.54 | 0.47 | 0.45 | 3.51 |
Profit After Tax | 0.91 | 0.54 | 0.46 | 0.46 | 3.42 |
Operating Profit after Depreciation | 6.44 | 5.80 | 6.18 | 5.33 | 8.32 |
Company | Price | Market Cap (in ₹ Cr) |
---|---|---|
Megasoft Ltd | ₹79.32 | ₹585.14 |
Sun Pharmaceuticals Industries Ltd | ₹1,745.25 | ₹4,18,743.94 |
Divis Laboratories Ltd | ₹5,733.60 | ₹1,52,209.07 |
Cipla Ltd | ₹1,458.15 | ₹1,17,762.24 |
Torrent Pharmaceuticals Ltd | ₹3,357.15 | ₹1,13,616.11 |
Mankind Pharma Ltd | ₹2,488.40 | ₹1,02,663.15 |
07 Nov 2024, 02:15 pm
06 Sep 2024, 05:41 pm
06 Sep 2024, 04:38 pm
22 Aug 2024, 02:45 pm
08 Aug 2024, 11:02 am